Soleno Therapeutics (SLNO) Net Income towards Common Stockholders (2016 - 2017)
Historic Net Income towards Common Stockholders for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$544000.0.
- Soleno Therapeutics' Net Income towards Common Stockholders rose 7918.41% to -$544000.0 in Q4 2017 from the same period last year, while for Sep 2018 it was -$544000.0, marking a year-over-year increase of 9039.27%. This contributed to the annual value of -$175.8 million for FY2024, which is 35315.16% down from last year.
- Per Soleno Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$544000.0 for Q4 2017, which was up 7918.41% from -$1.3 million recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Net Income towards Common Stockholders ranged from a high of -$544000.0 in Q4 2017 and a low of -$6.4 million during Q3 2016
- Over the past 5 years, Soleno Therapeutics' median Net Income towards Common Stockholders value was -$2.0 million (recorded in 2014), while the average stood at -$2.3 million.
- Per our database at Business Quant, Soleno Therapeutics' Net Income towards Common Stockholders crashed by 37925.27% in 2014 and then surged by 8024.87% in 2017.
- Soleno Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$869278.0 in 2013, then plummeted by 379.25% to -$4.2 million in 2014, then soared by 31.72% to -$2.8 million in 2015, then increased by 8.13% to -$2.6 million in 2016, then skyrocketed by 79.18% to -$544000.0 in 2017.
- Its last three reported values are -$544000.0 in Q4 2017, -$1.3 million for Q3 2017, and -$913000.0 during Q2 2017.